AGI 101HAlternative Names: AGI-101
Latest Information Update: 02 May 2016
At a glance
- Originator AGIRx
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma
Most Recent Events
- 21 Apr 2016 AGIRx terminates a phase I/II trial in Malignant melanoma in Poland (NCT00716495)
- 31 May 2015 AGI 101H is still in clinical development for Malignant melanoma in Poland